57 filings
Page 3 of 3
8-K
wu0im6b0m8 l9
13 May 22
Vallon Pharmaceuticals Announces $3.9 Million Registered Direct Offering
5:12pm
8-K
n0n2cjli 027ui
12 May 22
Vallon Pharmaceuticals Reports Additional Pharmacokinetic and Pharmacodynamic Data from SEAL Study of ADAIR
8:37am
8-K
0jil u3bxl
9 May 22
Vallon Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
4:08pm
8-K
t276htn r083
22 Apr 22
Vallon Pharmaceuticals Announces Review of Strategic Alternatives
9:17am
8-K
6qn2j
30 Mar 22
Departure of Directors or Certain Officers
9:26am
8-K
gj8dzb18
21 Mar 22
Vallon Pharmaceuticals Announces Topline Results of its Pivotal SEAL Study for Lead Program, ADAIR, for the Treatment of ADHD
7:01am
8-K
4ozcw66jun
28 Feb 22
Vallon Pharmaceuticals Announces Appointment of Meenu Karson to Board of Directors
4:08pm
8-K
7rl9m47tag9kol2dhl
14 Feb 22
Vallon Pharmaceuticals Reports Fiscal Year 2021 Financial Results and Provides Business Update
4:23pm
8-K
f2x xvuu0jmptf6v8
23 Dec 21
Vallon Pharmaceuticals Announces Achievement of Last Patient Last Visit in Pivotal SEAL Study for Lead Program, ADAIR
8:36am
8-K
738 dj5cr8z
12 Nov 21
Vallon Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update
8:06am
8-K
upaabdpg1jr016yyrij3
12 Oct 21
Vallon Pharmaceuticals Provides Update on Recent Pipeline and Corporate Advancements
9:02am
8-K
g0xo 7rr278
10 Aug 21
Vallon Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update
8:06am
8-K
ua8kj
13 May 21
Vallon Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update
8:45am
8-K
bdwqv
23 Apr 21
Departure of Directors or Certain Officers
4:40pm
8-K
8hya0o9p
14 Apr 21
Vallon Pharmaceuticals Continues Advancement of Pivotal Study in Lead Development Program, ADAIR, Toward Potential Approval
12:00am
8-K
16zn8q2v
26 Feb 21
Regulation FD Disclosure
4:37pm
8-K
q4g48j9s i69dj2p1nb
16 Feb 21
Vallon Pharmaceuticals Announces Pricing of Initial Public Offering
6:02am